The Yin and Yang of myelodysplastic syndromes and autoimmunity: The paradox of autoimmune disorders responding to therapies specific for MDS

被引：7
作者：
Fozza, Claudio [1 ]
La Nasa, Giorgio [2 ]
Caocci, Giovanni [2 ]
机构：
[1] Univ Sassari, Dept Med Surg & Expt Sci, Hematol Unit, Viale San Pietro 12, I-07100 Sassari, Italy
[2] Univ Cagliari, Dept Med Sci, Hematol Unit, Cagliari, Italy
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2019年 / 142卷
关键词：
Myelodysplastic syndromes; Immunotherapy; Autoimmunity; Autoimmune manifestations; STEM-CELL TRANSPLANTATION; INTESTINAL BEHCETS-DISEASE; CORD BLOOD TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; T-CELLS; IMMUNOLOGICAL ABNORMALITIES; AZACITIDINE; 5-AZACYTIDINE; LENALIDOMIDE; EFFICACY;
D O I：
10.1016/j.critrevonc.2019.07.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The biological milieu and clinical picture of myelodysplastic syndromes (MDS) is characterised by a variety of immune mechanisms and manifestations, including an increased frequency of autoimmune disorders. The present review will try to shed some light on the potential clinical and pathogenetic implications of these immune processes in MDS by focusing on the beneficial effects exerted by some MDS-modifying therapies on autoimmune manifestations.
引用
收藏
页码：51 / 57
页数：7
相关论文
共 65 条
[1]   Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study [J].
Ades, Lionel ;
Boehrer, Simone ;
Prebet, Thomas ;
Beyne-Rauzy, Odile ;
Legros, Laurence ;
Ravoet, Christophe ;
Dreyfus, Francois ;
Stamatoullas, Aspasia ;
Chaury, Marie Pierre ;
Delaunay, Jacques ;
Laurent, Guy ;
Vey, Norbert ;
Burcheri, Sara ;
Mbida, Rose-Marie ;
Hoarau, Natacha ;
Gardin, Claude ;
Fenaux, Pierre .
BLOOD, 2009, 113 (17) :3947-3952
[2]   Treating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells [J].
Al Ustwani, Omar ;
Wallace, Paul K. ;
Ambrus, Julian, Jr. ;
Wetzler, Meir .
LEUKEMIA RESEARCH, 2011, 35 (05) :E35-E36
[3]   Risks of myeloid malignancies in patients with autoimmune conditions [J].
Anderson, L. A. ;
Pfeiffer, R. M. ;
Landgren, O. ;
Gadalla, S. ;
Berndt, S. I. ;
Engels, E. A. .
BRITISH JOURNAL OF CANCER, 2009, 100 (05) :822-828
[4]  
BILLSTROM R, 1995, EUR J HAEMATOL, V55, P42
[5]   Azacitidine differentially affects CD4pos T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes [J].
Bontkes, Hetty J. ;
Ruben, Jurjen M. ;
Alhan, Canan ;
Westers, Theresia M. ;
Ossenkoppele, Gert J. ;
van de Loosdrecht, Arjan A. .
LEUKEMIA RESEARCH, 2012, 36 (07) :921-930
[6]   The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome [J].
Costantini, Benedetta ;
Kordasti, Shahram Y. ;
Kulasekararaj, Austin G. ;
Jiang, Jie ;
Seidl, Thomas ;
Abellan, Pilar Perez ;
Mohamedali, Azim ;
Thomas, Nicolas Shaun B. ;
Farzaneh, Farzin ;
Mufti, Ghulam J. .
HAEMATOLOGICA, 2013, 98 (08) :1196-1205
[7]   Systemic and Immune Manifestations in Myelodysplasia: A Multicenter Retrospective Study [J].
de Hollanda, A. ;
Beucher, A. ;
Henrion, D. ;
Ghali, A. ;
Lavigne, C. ;
Levesque, H. ;
Hamidou, M. ;
Subra, J. F. ;
Ifrah, N. ;
Belizna, C. .
ARTHRITIS CARE & RESEARCH, 2011, 63 (08) :1188-1194
[8]   A Case of Myelodysplastic Syndrome with Intestinal Behcet's Disease-Like Symptoms Treated by Prednisolone and Azacitidine [J].
Endo, Masatsugu ;
Sekikawa, Akira ;
Tsumura, Takehiko ;
Maruo, Takanori ;
Osaki, Yukio .
AMERICAN JOURNAL OF CASE REPORTS, 2015, 16 :827-831
[9]   PARANEOPLASTIC AUTOIMMUNE PHENOMENA IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES - RESPONSE TO IMMUNOSUPPRESSIVE THERAPY [J].
ENRIGHT, H ;
JACOB, HS ;
VERCELLOTTI, G ;
HOWE, R ;
BELZER, M ;
MILLER, W .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 91 (02) :403-408
[10]  
Erden Abdulsamet, 2018, Drug Metabolism and Personalized Therapy, V33, P105, DOI 10.1515/dmpt-2018-0002
1234567